Wave Life Sciences (WVE) Cash from Operations (2014 - 2026)
Wave Life Sciences' (WVE) quarterly Cash from Operations came in at 53582000.0 in Q2 2026, down 16.45% YoY from 64133369.34 in Q2 2025, and up 10.03% on a QoQ basis from 59553000.0 in Q1 2026.
Wave Life Sciences (WVE) Cash from Operations (2014 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 13 years of Cash from Operations data on file, last reported at 53582000.0 in Q2 2026.
- Quarterly Cash from Operations fell 16.45% year-over-year to 53582000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 191577000.0 (up 3.82% YoY) and the FY2025 annual result came in at 187493000.0, down 24.15% from the prior year.
- Cash from Operations improved to 53582000.0 in Q2 2026, from 59553000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 85522000.0 in Q1 2023 to a low of 63039000.0 in Q1 2025.
- A 5-year average of 33270333.33 and a median of 35857000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 375.47% — and 2023, when it soared 314.49%.
- Tracing WVE's Cash from Operations over 5 years: stood at 33440000.0 in 2022, then increased by 0.6% to 33239000.0 in 2023, then sank by 31.32% to 43648000.0 in 2024, then advanced by 22.62% to 33776000.0 in 2025, then tumbled by 58.64% to 53582000.0 in 2026.
- The last three Cash from Operations figures came in at 53582000.0 (Q2 2026), 59553000.0 (Q1 2026), and 33776000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - | -53.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.58 Mn |
| Jun 30, 2026 | -53.58 Mn |
| Mar 31, 2026 | -59.55 Mn |
| Mar 31, 2026 | -59.55 Mn |
| Dec 31, 2025 | -33.78 Mn |
| Dec 31, 2025 | -33.78 Mn |
| Sep 30, 2025 | -44.67 Mn |
| Sep 30, 2025 | -44.67 Mn |
| Jun 30, 2025 | -46.01 Mn |
| Jun 30, 2025 | -46.01 Mn |
| Mar 31, 2025 | -63.04 Mn |
| Mar 31, 2025 | -63.04 Mn |
| Dec 31, 2024 | -43.65 Mn |
| Dec 31, 2024 | -43.65 Mn |
| Sep 30, 2024 | -46.48 Mn |
| Sep 30, 2024 | -46.48 Mn |
| Jun 30, 2024 | -27.47 Mn |
| Jun 30, 2024 | -27.47 Mn |
| Mar 31, 2024 | -33.43 Mn |
| Mar 31, 2024 | -33.43 Mn |